Roche wins Japan approval for personalised cancer drug Rozlytrek

Credit: REUTERS/Arnd Wiegmann

Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world's biggest maker of cancer drugs pushes ahead in personalised medicines that require a biomarker test to identify prospective patients.

ZURICH, June 18 (Reuters) - Swiss drugmaker Roche ROG.S on Tuesday won approval in Japan for Rozlytrek as the world's biggest maker of cancer drugs pushes ahead in personalised medicines that require a biomarker test to identify prospective patients.

Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumours, across 10 different tumour types, including those with central nervous system metastases.

(Reporting by John Miller Editing by Michelle Martin)

((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters Messaging: j.miller.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More